Promising Alzheimer’s Therapies ANAVEX 2-73, ANAVEX PLUS Approved For Phase 2 Trials

Promising Alzheimer’s Therapies ANAVEX 2-73, ANAVEX PLUS Approved For Phase 2 Trials
Anavex Life Sciences Corp. will initiate a Phase 2a clinical trial for the treatment of Alzheimer’s disease with their compounds – ANAVEX 2-73 and ANAVEX PLUS – after receiving regulatory approval by the Ethics Committee in Australia. ANAVEX 2-73, an orally available drug candidate, is under investigation to treat Alzheimer’s disease. In previous preclinical studies, ANAVEX

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *